#United States #San Diego #Class Action #Investor Lawsuit #Capricor Therapeutics

Capricor Therapeutics Faces Class Action Lawsuit

In a significant development for investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR), the law firm of Robbins Geller Rudman & Dowd LLP has announced a vital opportunity for those who purchased shares during a specified period. If you acquired Capricor securities between December 17, 2025 and July 26, 2026, you may yet have time to engage in a class action lawsuit against the company. The deadline to apply as the lead plaintiff in this case is set for September 28, 2026.

Background on Capricor Therapeutics

Capricor Therapeutics is a biotech firm dedicated to developing innovative therapies aimed at treating Duchenne muscular dystrophy (DMD), a rare genetic disorder that leads to progressive muscle degeneration and early demise. Their leading product candidate, Deramiocel, is a cell therapy designed to mitigate heart and skeletal muscle complications associated with this disorder. However, recent allegations have arisen that cast doubt on the integrity of the data submitted to the FDA regarding this product.

Investigations into Capricor's practices reveal claims suggesting the company made misleading statements regarding their clinical trial methodologies. Allegedly, they altered a critical pre-specified statistical analysis plan (SAP) to favor the interpretation of their product's efficacy.

Moreover, it has been claimed that the alterations weren't approved by the FDA before they resubmitted their Biologics License Application (BLA). These modifications have led to serious concerns regarding the company's ability to demonstrate substantial evidence of Deramiocel's effectiveness, consequently jeopardizing potential regulatory approval.

Recent Developments and Impact on Shareholders

On July 27, 2026, prior to market hours, the FDA released preliminary documents outlining major concerns about Capricor’s presentation and the data integrity associated with Deramiocel. The findings, which suggested that the company made significant changes to its statistical analysis leading to misleading representations, triggered alarm across the investor community. Following this news, Capricor's stock witnessed a staggering decline of 64%.

The advisory committee's meeting on July 29, 2026, further underscored investors' fears, as the committee ultimately rejected Deramiocel's efficacy based on incomplete and badly justified data analyses, resulting in an additional stock drop of 36%.

Class Action Lawsuit Details

The core of the class action lawsuit alleges that Capricor, along with certain executives, violated the Securities Exchange Act by failing to disclose critical information regarding the regulatory hurdles they faced. Investors who sustained notable financial losses during the class period are encouraged to come forward.

The Private Securities Litigation Reform Act of 1995 permits individuals who purchased shares during the designated period to apply for lead plaintiff status. The lead plaintiff serves as a representative for all affected investors and has the authority to select legal counsel for the case. While involvement as lead plaintiff is advantageous, it is essential to note that it does not impact an investor's chance to recover potential financial reparations from the lawsuit.

About Robbins Geller

Known for its prominent role in securities fraud litigation, Robbins Geller Rudman & Dowd LLP leads in representing investors and has secured over $8.4 billion in recoveries in the last five years alone. Their expertise underscores the seriousness of the claims against Capricor and the potential for reparations for aggregate investor losses surrounding this case.

Interested investors are encouraged to reach out via the firm's contact information for more details. This lawsuit presents a significant opportunity for shareholders who have experienced losses to hold Capricor accountable for their alleged misconduct.

For further information, potential plaintiffs can visit Robbins Geller's website or connect directly with attorneys Ken Dolitsky and Michael Albert at 800-851-7783.

Ensure you act promptly—September 28, 2026, is looming.